Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

DARE vs MTNB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MTNB Captures Overall Composite Edge (54.6 HOLD vs 43.1 HOLD), While DARE Leads 3–1 on Growth & Valuation Pillars

MTNB Overall Winner 6-Pillar Tally: DARE 3 – 1 MTNB (2 Tie) Matrix Metrics: DARE 4 – 4 MTNB

As of Nov 19, 2026, Matinas BioPharma Holdings, Inc. (MTNB) captures the overall head-to-head institutional edge over Dare Bioscience, Inc. (DARE) on higher Unified Composite conviction (54.6/100 HOLD vs. 43.1/100 HOLD) after splitting the core matrix 4–4 (led by Profitability & Quality), while DARE wins 3–1 across the 6-pillar growth and valuation breakdown. DARE trades at $0.45 (1.3x Forward P/E, -746.1% operating margin) versus MTNB at $0.81 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: MTNB earns the overall head-to-head edge with a stronger Unified Composite Score (54.6/100 HOLD vs. DARE 43.1/100 HOLD) and -7.20β · 147% Vol risk profile, whereas DARE leads top-line expansion (+2005.6% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: DARE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.9); meanwhile MTNB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 33.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DARE vs MTNB
DARE NASDAQ
Dare Bioscience, Inc. Common Stock
Pharmaceutical Preparations
$0.45
+0.44% 1D
Market Cap $8.8M
TTM Revenue $1.4M
Forward P/E 1.3x
Beta / 30D Vol 1.52β · 112% Vol
Unified Composite Score
43.1 / 100 HOLD
Tech 35.0 Fund 46.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.0%), weak momentum, RSI 26
RSI-14: 25.9 · SMA20: $0.63 · SMA50: $0.71
MTNB NYSE American Head-to-Head Winner
Matinas BioPharma Holdings, Inc.
Pharmaceutical Preparations
$0.81
-10.98% 1D
Market Cap $979,904
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -7.20β · 147% Vol
Unified Composite Score
54.6 / 100 HOLD
Tech 53.0 Fund 58.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 33
RSI-14: 33.0 · SMA20: $1.26 · SMA50: $1.47

6-Pillar Scorecard Institutional Category Breakdown (DARE 3 – 1 MTNB)

Columns: Metric · DARE · MTNB
1. Valuation Multiples DARE
Forward P/E 1.3x N/M
Trailing P/E 1.3x N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale DARE
Revenue Growth (YoY) +2005.6% -100.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $1.4M N/A
Market Cap $8.8M $979,904
3. Profitability & Quality MTNB
Gross Margin N/A N/A
Operating Margin -746.1% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -407.1% -147.5%
4. Balance Sheet & Cash Flow DARE
Cash Generation (TTM) -$12M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $12M Net Cash $1.2M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DARE (4) vs MTNB (4)
Institutional Metric DARE MTNB Criterion Row Edge
Market Capitalization
Scale
$8.8M $979,904 Larger Scale Tie
Trailing P/E Ratio
Valuation
1.3x N/M Lower Multiple DARE
Forward P/E Ratio
Valuation
1.3x N/M Lower Multiple DARE
Revenue Growth (YoY)
Growth
+2005.6% -100.0% Higher Growth DARE
Operating Margin (TTM)
Profitability
-746.1% 0.0% Higher Margin MTNB
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-407.1% -147.5% Higher ROE MTNB
52-Week Range Position
Momentum
1% ($0–$4) 22% ($0–$3) Stronger Trend MTNB
Beta / 30D Volatility
Risk Regime
1.52β · 112% Vol -7.20β · 147% Vol Lower Realized Risk DARE
Unified Institutional Score
Composite Signal
43.1 / 100 (HOLD) 54.6 / 100 (HOLD) Higher Composite MTNB
Trailing 12M Revenue (USD)
Operating Scale
$1.4M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$12M ($12M Net Cash) N/A ($1.2M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DARE +12.4 pp
DARE: -34.3% · MTNB: -46.7%
3M Horizon MTNB +352.36 pp
DARE: -44.87% · MTNB: +307.49%
6M Horizon MTNB +102.17 pp
DARE: -81.24% · MTNB: +20.93%
1Y Horizon MTNB +43.26 pp
DARE: -74.61% · MTNB: -31.35%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period DARE Revenue MTNB Revenue DARE Op. Margin MTNB Op. Margin Margin Leader
FY2018 N/A $0M N/A -12230.9% MTNB
FY2019 N/A $0M N/A -21067.4% MTNB
FY2020 N/A $0M N/A -15288.4% MTNB
FY2021 N/A $0M N/A -74954.5% MTNB
FY2022 $10M $0M -313.9% -771.3% DARE
FY2023 $0M $0M -1101.9% -2168.4% DARE
FY2024 $0M N/A -239692.2% N/A DARE
FY2025 $0M N/A -1315.5% N/A DARE

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DARE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact DARE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MTNB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MTNB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DARE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $8.8M market capitalization and -746.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MTNB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $979,904 market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ DARE vs MTNB Key Questions & Quantitative Answers

As of Nov 19, 2026, Matinas BioPharma Holdings, Inc. (MTNB) captures the overall head-to-head institutional edge over Dare Bioscience, Inc. (DARE) on higher Unified Composite conviction (54.6/100 HOLD vs. 43.1/100 HOLD) after splitting the core matrix 4–4 (led by Profitability & Quality), while DARE wins 3–1 across the 6-pillar growth and valuation breakdown. DARE trades at $0.45 (1.3x Forward P/E, -746.1% operating margin) versus MTNB at $0.81 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: MTNB earns the overall head-to-head edge with a stronger Unified Composite Score (54.6/100 HOLD vs. DARE 43.1/100 HOLD) and -7.20β · 147% Vol risk profile, whereas DARE leads top-line expansion (+2005.6% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: DARE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.9); meanwhile MTNB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 33.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DARE leads the Growth & Scale pillar: DARE posts +2005.6% YoY revenue growth and +0.0% YoY earnings growth on $1.4M TTM revenue (N/A gross margin, -746.1% operating margin), compared with MTNB at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), DARE cumulative revenue shifted N/A while MTNB shifted N/A. In operating R&D and SG&A reinvestment, DARE deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MTNB.

DARE screens cheaper on headline valuation multiples. DARE trades at 1.3x Forward P/E, 1.3x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas MTNB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DARE (-407.1% ROE) versus MTNB (-147.5% ROE) capital efficiency.

In options market volatility and institutional positioning, DARE carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.52β · 112% Vol realized risk). By comparison, MTNB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-7.20β · 147% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.